Want to see OBIO full AI Analyst Report?
OBIO Stock Chart & Stats
$3.74
$0.10(2.75%)
At close: 4:00 PM EDT
$3.74
$0.10(2.75%)
Day’s Range― - ―
52-Week Range$2.20 - $5.78
Previous Close$3.74
Volume149.34K
Average Volume (3M)423.89K
Market Cap
$326.37M
Enterprise Value$246.24
Total Cash (Recent Filing)$109.96M
Total Debt (Recent Filing)$21.77M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 16, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding60,105,050
10 Day Avg. Volume206,441
30 Day Avg. Volume423,889
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.13
Price to Sales (P/S)5.92
P/FCF Ratio-4.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside167.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$548.29K
Bulls Say, Bears Say
Bulls Say
Revenue Scale-Up And High Gross MarginThe move from roughly $2–4M of revenue in 2022–2024 to more than $32M recently shows meaningful commercial progress. The near-99% gross margin also indicates that partnered revenue can carry substantial contribution potential.
Modest LeverageVery limited debt reduces interest burden and near-term balance-sheet pressure, giving Orchestra BioMed greater flexibility to fund clinical programs. This is an important structural advantage while the company remains loss-making and dependent on external financing.
Capital-Light Partnership ModelA collaboration-led model can provide access to partner funding, regulatory expertise and commercial infrastructure without requiring Orchestra BioMed to build a large sales organization. Successful partnerships could therefore improve scalability and capital efficiency.
Bears Say
Persistent Net LossesLarge losses across the reported periods show that the current revenue base remains insufficient to support the company’s operating structure. Sustained negative profitability could require additional financing and may limit flexibility in advancing multiple programs.
Heavy Operating Cash BurnCash consumption closely tracks net losses, indicating that the deficit is translating into a substantial funding requirement rather than being mainly non-cash. Continued clinical development may therefore depend on financing, partner contributions or milestone receipts.
Milestone-Driven Revenue VolatilityRevenue tied to collaborations, clinical milestones, regulatory events and commercialization can be uneven and difficult to forecast. The slight TTM decline after the 2025 step-up highlights the risk that reported revenue may fluctuate with partner execution and program timing.
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $2.20 and its highest was $5.78 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Orchestra BioMed Holdings’s market cap is $326.37M.
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is Nov 16, 2026 which is in 85 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on Aug 10, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.392 by $0.012.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -0.41.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 60,105,050 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.392. Following the earnings report the stock price went down -1.345%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Currently, no hedge funds are holding shares in OBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orchestra BioMed Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (167.38% Upside)
$10.00 (167.38% Upside)
Blogger Sentiment
Bullish
OBIO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $19.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
170.17%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Orchestra BioMed Holdings (OBIO) is a biomedical technology company focused on developing device-based therapies aimed at treating cardiovascular and related diseases. The company’s core activities center on advancing and clinically validating its medical device programs and working with larger strategic partners to commercialize them.
OBIO Stock 12 Month Forecast
Average Price Target
$10.00
▲(167.38% Upside)
Technical Analysis
Cardiff Oncology
―
Greenwich LifeSciences
―
Climb Bio
―
Cognition Therapeutics
―
Pyxis Oncology
―
Ownership Overview
22.07% Insiders
4.88% Mutual Funds
30.15% Other Institutional Investors
35.70% Public Companies and
Individual Investors